CytomX Therapeutics, Inc. CTMX
2.19 USD +0.05 (+2.34%)
At closeNov 6, 2026, 4:20 PM EST
2.19 0.00 0.00%
After hours · Nov 6, 4:20 PM ET
2.12 Day range 2.27
2.14 52-week range 6.75
- YTD
- -48.59%
- 1 year
- -47.73%
News
benzinga.com Wedbush Maintains Outperform on CytomX Therapeutics, Raises Price Target to $12 Wedbush analyst Robert Driscoll maintains CytomX Therapeutics (NASDAQ:CTMX) with a Outperform and raises the price target from $11 to $12.
marketbeat.com CytomX Therapeutics Q3 Earnings Call Highlights CytomX Therapeutics NASDAQ: CTMX plans to provide a January update on its lead cancer drug candidate, Varseta-M, as it prepares for a potential registrational study in metastatic colorectal cancer in…
benzinga.com CytomX Therapeutics Q3 2026 Earnings Call Transcript CytomX Therapeutics (NASDAQ:CTMX) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com CytomX Therapeutics Q3 EPS $(0.09) Beats $(0.10) Estimate, Sales $1.688M Miss $4.925M Estimate CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.10) by 0 percent. This is unchanged from the same period last year.…
seekingalpha.com CytomX Therapeutics: Trading Near Cash Value While Varseta-M Heads Toward Pivotal Trials CytomX Therapeutics is rated Buy, driven by positive clinical data for Varseta-M and a robust $367M cash runway after significant dilution. Varseta-M, targeting late-line colorectal cancer, achieved…
globenewswire.com CytomX Therapeutics to Present at Upcoming November Investor Conferences SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that…